FTC Will Investigate Anti-Competitive Rebating But Any Enforcement Action Would Take Time

Commission policy statement highlights situations where rebates lead to formulary exclusion of lower-priced insulin. But concern is also relevant for other drug classes, including highly-anticipated coverage decisions for biosimilars to Humira.

Rebate
Investigation Starts With PBMs But Manufacturers Could Be Implicated Too • Source: Shutterstock

The Federal Trade Commissioner has unanimously adopted a policy statement articulating its commitment to investigating rebates paid by drug manufacturers to pharmacy benefit managers in exchange for providing less favorable coverage to generics and biosimilars.

Approved 16 June, the statement notes that “nothing prevents drug manufacturers, PBMs, and health plans from negotiating good-faith rebates and...

More from Market Access

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Trump Administration Closer to Unprecedented Drug Price Transparency Requirements

 
• By 

New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.

More from Pink Sheet

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By 

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”